leflunomide has been researched along with Body Weight in 11 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " It was evaluated, in comparison with azathioprine (AZA) and methylprednisolone acetate (MPA), for its therapeutic effects on the glomerulonephritis induced in rats by rabbit antiserum against the rat glomerular basement membrane." | 7.68 | Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by the antibasement membrane antibody in rats. ( Gotoh, K; Hayashi, S; Inazu, M; Inoue, T; Ogawa, T, 1991) |
| "The possible link between LEF and interstitial lung disease (ILD) has evoked increasing concern." | 5.35 | Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. ( Inokuma, S; Matsuda, T; Otsuka, T; Saeki, Y; Sagawa, A; Sato, T; Sawada, T; Takemura, T; Takeuchi, T, 2009) |
| " It was evaluated, in comparison with azathioprine (AZA) and methylprednisolone acetate (MPA), for its therapeutic effects on the glomerulonephritis induced in rats by rabbit antiserum against the rat glomerular basement membrane." | 3.68 | Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by the antibasement membrane antibody in rats. ( Gotoh, K; Hayashi, S; Inazu, M; Inoue, T; Ogawa, T, 1991) |
| "Based on a pharmacokinetic (PK) study assessing the relative bioavailability of teriflunomide sodium compared to leflunomide, a population pharmacokinetic (Pop PK) analysis was firstly conducted using non-linear mixed effect model." | 1.51 | A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus. ( Chen, X; Hu, P; Jiang, J; Liu, D; Wu, Y; Yao, X, 2019) |
| "Diabetic nephropathy is one of the most common chronic complications of diabetes with poor efficacy of clinical treatment." | 1.43 | Protective effects of leflunomide on renal lesions in a rat model if diabetic nephropathy. ( He, T; Ji, Y; Lv, W; Wang, J; Zhang, Q, 2016) |
| "Treatment with prednisone was associated with greater weight gain (β = 0." | 1.43 | Changes in Body Mass Related to the Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis. ( Baker, JF; Cannella, A; Cannon, GW; Caplan, L; Davis, L; Ibrahim, S; Jorgenson, E; Michaud, K; Mikuls, TR; Sauer, BC; Teng, CC, 2016) |
| "The possible link between LEF and interstitial lung disease (ILD) has evoked increasing concern." | 1.35 | Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. ( Inokuma, S; Matsuda, T; Otsuka, T; Saeki, Y; Sagawa, A; Sato, T; Sawada, T; Takemura, T; Takeuchi, T, 2009) |
| "Leflunomide is a pyrimidine synthesis inhibitor used in the treatment of rheumatoid arthritis." | 1.33 | Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis. ( Bhargava, VO; Kovacs, SJ; Ludden, TM; Shi, J; Wang, Y, 2005) |
| "Leflunomide (Lef) is a novel immunosuppressant that can prevent islet allograft and xenograft rejection." | 1.30 | In vivo effects of leflunomide on normal pancreatic islet and syngeneic islet graft function. ( Chong, AS; Foster, P; Gebel, H; Guo, Z; Jensik, SC; McChesney, L; Mital, D; Sankary, HN; Shen, J; Williams, JW, 1997) |
| " It is also well tolerated on long-term administration and, by virtue of this fact, is a potentially suitable candidate for clinical transplantation." | 1.29 | The immunomodulatory effect of leflunomide in rat cardiac allotransplantation. ( Achilleos, O; Antoniou, E; Buckels, J; Candinas, D; D'Silva, M; DeRoover, A; Germenis, A; Lee, S; Mayer, D; Stavropoulos, C, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yao, X | 1 |
| Wu, Y | 1 |
| Jiang, J | 1 |
| Chen, X | 1 |
| Liu, D | 1 |
| Hu, P | 1 |
| Zhang, Q | 1 |
| Ji, Y | 1 |
| Lv, W | 1 |
| He, T | 1 |
| Wang, J | 1 |
| Baker, JF | 1 |
| Sauer, BC | 1 |
| Cannon, GW | 1 |
| Teng, CC | 1 |
| Michaud, K | 1 |
| Ibrahim, S | 1 |
| Jorgenson, E | 1 |
| Davis, L | 1 |
| Caplan, L | 1 |
| Cannella, A | 1 |
| Mikuls, TR | 1 |
| Sawada, T | 1 |
| Inokuma, S | 1 |
| Sato, T | 1 |
| Otsuka, T | 1 |
| Saeki, Y | 1 |
| Takeuchi, T | 1 |
| Matsuda, T | 1 |
| Takemura, T | 1 |
| Sagawa, A | 1 |
| Wei, YH | 1 |
| Li, Y | 1 |
| Qiang, CJ | 1 |
| Shi, J | 1 |
| Kovacs, SJ | 1 |
| Wang, Y | 1 |
| Ludden, TM | 1 |
| Bhargava, VO | 1 |
| D'Silva, M | 2 |
| Candinas, D | 2 |
| Achilleos, O | 2 |
| Lee, S | 1 |
| Antoniou, E | 1 |
| DeRoover, A | 1 |
| Germenis, A | 1 |
| Stavropoulos, C | 1 |
| Buckels, J | 1 |
| Mayer, D | 1 |
| Guo, Z | 1 |
| Chong, AS | 1 |
| Shen, J | 1 |
| Foster, P | 1 |
| Sankary, HN | 1 |
| McChesney, L | 1 |
| Mital, D | 1 |
| Jensik, SC | 1 |
| Gebel, H | 1 |
| Williams, JW | 1 |
| Hausen, B | 1 |
| Boeke, K | 1 |
| Berry, GJ | 1 |
| Gummert, JF | 1 |
| Christians, U | 1 |
| Morris, RE | 1 |
| Lee, SJ | 1 |
| Dalgic, A | 1 |
| Miki, C | 1 |
| Mayer, AD | 1 |
| McMaster, P | 1 |
| Ogawa, T | 1 |
| Inazu, M | 1 |
| Gotoh, K | 1 |
| Inoue, T | 1 |
| Hayashi, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Importance of Therapeutic Monitoring of Orally Administered Disease-modifying Drugs Used in the Treatment of Multiple Sclerosis[NCT05112484] | 600 participants (Anticipated) | Observational | 2023-10-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 other studies available for leflunomide and Body Weight
| Article | Year |
|---|---|
A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus.
Topics: Arthritis, Rheumatoid; ATP Binding Cassette Transporter, Subfamily G, Member 2; Body Weight; Crotona | 2019 |
Protective effects of leflunomide on renal lesions in a rat model if diabetic nephropathy.
Topics: Actins; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Blood Urea Nitrogen; Body | 2016 |
Changes in Body Mass Related to the Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Body Mass Index; Body Weight; | 2016 |
Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Body Weight; Female; Humans; Isoxazoles; Japan; L | 2009 |
Effects and mechanisms of FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor, on adjuvant arthritis in rats.
Topics: Animals; Arthritis, Experimental; Body Weight; Cell Proliferation; China; Disease Models, Animal; Do | 2004 |
Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis.
Topics: Adolescent; Antirheumatic Agents; Arthritis, Juvenile; Body Weight; Child; Child, Preschool; Drug Ad | 2005 |
The immunomodulatory effect of leflunomide in rat cardiac allotransplantation.
Topics: Animals; Blood Urea Nitrogen; Body Weight; Graft Rejection; Graft Survival; Heart Transplantation; I | 1995 |
In vivo effects of leflunomide on normal pancreatic islet and syngeneic islet graft function.
Topics: Animals; Body Weight; Cyclosporine; Immunosuppressive Agents; Islets of Langerhans; Islets of Langer | 1997 |
Potentiation of immunosuppressive efficacy by combining the novel leflunomide analog, HMR 279, with microemulsion cyclosporine in a rat lung transplant model.
Topics: Amides; Aniline Compounds; Animals; Biotransformation; Body Weight; Chromatography, High Pressure Li | 1999 |
The immunomodulatory effects of a novel agent, leflunomide, in rat cardiac allotransplantation.
Topics: Animals; Body Weight; Cyclosporine; Graft Rejection; Graft Survival; Heart Transplantation; Immunosu | 1994 |
Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by the antibasement membrane antibody in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Anti-Idiotypic; Azathioprine; Basement | 1991 |